Finance

Beta
Lists
2096:HKG
Simcere Pharmaceutical Group Ltd
HK$9.87
+2.28%
(+0.22) 1D
Jun 5, 4:09:10 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2096...
Open
HK$9.65
High
HK$9.90
Low
HK$9.64
Mkt. cap
25.59B
Avg. vol.
6.07M
Volume
5.65M
Dividend
2.07%
Quarterly dividend
HK$0.05
Ex-dividend date
Jun 17, 2026
P/E ratio
15.72
52-wk high
HK$15.08
52-wk low
HK$9.52
EPS
HK$0.63
Shares outstanding
2.60B
No. of employees
7K
Open
HK$9.65
High
HK$9.90
Low
HK$9.64
Mkt. cap
25.59B
Avg. vol.
6.07M
Volume
5.65M
Dividend
2.07%
Quarterly dividend
HK$0.05
Ex-dividend date
Jun 17, 2026
P/E ratio
15.72
52-wk high
HK$15.08
52-wk low
HK$9.52
EPS
HK$0.63
Shares outstanding
2.60B
No. of employees
7K
Analyst outlook
Analyst Ratings
Based on 4 analysts giving stock ratings to 2096 in the past 3 months
Strong Buy
Buy
4
Hold
0
Sell
0
12 month forecast
Based on 4 Wall Street analysts offering 12 month price targets for 2096 in the last 3 months.
Highest
Current HK$9.87
HK$21.32 (+116.01%)
Average
HK$19.01 (+92.60%)
Lowest
HK$17.00 (+72.24%)
News stories
From sources across the web
Profile
Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia
About Simcere Pharmaceutical Group Ltd
CEORen Jinsheng
Employees7.04K
Founded1995
HeadquartersNanjing, Jiangsu, China
SectorPharmaceutical industry
Websitesimcere.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.79B
1.79B
2.07B
2.07B
Cost of goods sold
345.53M
345.53M
365.25M
365.25M
Cost of revenue
345.53M
345.53M
365.25M
365.25M
Research and development expenses
316.21M
316.21M
465.30M
465.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
807.37M
807.37M
949.52M
949.52M
Operating expense
1.09B
1.09B
1.36B
1.36B
Total operating expenses
1.44B
1.44B
1.72B
1.72B
Operating income
357.23M
357.23M
351.33M
351.33M
Other non operating income
-
-
-
-
EBT including unusual items
331.24M
331.24M
425.92M
425.92M
EBT excluding unusual items
350.09M
350.09M
348.89M
348.89M
Income tax expense
29.44M
29.44M
55.72M
55.72M
Effective tax rate
8.89%
8.89%
13.08%
13.08%
Other operating expenses
-34.30M
-34.30M
-56.27M
-56.27M
Net income
301.80M
301.80M
370.20M
370.20M
Net profit margin
16.84%
16.84%
17.86%
17.86%
Earnings per share
-
-
-
-
Interest and investment income
13.27M
13.27M
14.60M
14.60M
Interest expense
-24.27M
-24.27M
-23.63M
-23.63M
Net interest expenses
-10.99M
-10.99M
-9.03M
-9.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
409.84M
409.84M
449.72M
449.72M
Gain or loss from assets sale
-
-
-115.50K
-115.50K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer